Adams, N., Puwalski, S., Papagni, N., Leep, C., McCall, T.C., & Wanucha, D. (2023). Evaluating the impact of Food and Drug Administration-funded cooperative agreement programs on conformance with the Voluntary National Retail Food Regulatory Program Standards. J*ournal of Environmental Health*, *86*(4), 16–22.

Corresponding Author: Nicholas Adams, Senior Program Analyst, National Association of County and City Health Officials, 1201 Eye Street NW, Fourth Floor, Washington, DC 20005. Email: nadams@naccho.org.

Note. These supplemental tables were submitted by the authors as an extra resource should the reader want more information and has been posted online due to space limitations at https://www.neha.org/jeh-supplementals. The *Journal of Environmental Health* did not copy edit these tables, nor were they peer reviewed.

Supplemental Table A1: Self-Assessment Submission Time Effect Sizes for Comparisons						
	Cycle 1 v Cycle 2	Cycle 1 v Cycle 3	Cycle 1 v Cycle 4	Cycle 2 v Cycle 3	Cycle 2 v Cycle 4	Cycle 3 v Cycle 4
Total	0.3	0.2	0.5	0.4	0.6	0.2
	No Grant v Mentorship		No Grant v FDA CAP		No Grant v Mentorship & FDA CAP	
Cycle 1		0		0.4		0.3
Cycle 2		0.4		0.3		0.3
Cycle 3		0		0.2		0.5
Cycle 4		0.3		-		-
Overall		0.2		0.3		0.1
	Small v Mid-Size		Small v Large		Mid-Size v Large	
Cycle 1		0.2		0.3		0.2
Cycle 2		0.4		0.7		0.3
Cycle 3		0.4		0.2		0.2
Cycle 4	-		-		-	
Overall		0.2		0.4		0.2

Supplemental Table A2: Effect Sizes: Percentage of LHDs Submitting SA Updates						
	Cycle 1 v Cycle 2	Cycle 1 v Cycle 3	Cycle 1 v Cycle 4	Cycle 2 v Cycle 3	Cycle 2 v Cycle 4	Cycle 3 v Cycle 4
Total	-0.5	-0.5	-	0	-	-
	No Grant v Mentorship		No Grant v FDA CAP		No Grant v Mentorship & FDA CAP	
Cycle 1	-0.6		-0.1		-2.5	
Cycle 2	0.1		-0.33		0.1	
Cycle 3	0.1		-0.6		-0.9	
Cycle 4	-		-		-	
Overall	-0.4		-0.6		-0.75	
	Small v Mid-Size		Small v Large		Mid-Size v Large	
Cycle 1	0		0.1		0.1	
Cycle 2	0		-0.1		-0.1	
Cycle 3	-		-		-0.2	
Cycle 4	-		-		-	
Overall	-0.1		-0.1		-0.1	

Supplemental Table B1: Multiple Regression Models						
	Odds of Achieving Conformance with at least 1 Std via SA (OR 95% CI)	Odds of Achieving Conformance with at least 1 Std via VA (OR 95% CI)	Odds of at least 1 SA Updates During Cycle (OR 95% CI)	Mean Number of Stds Achieved via SA (IRR 95% CI)	Mean Number of Stds Achieved via VA (IRR 95% CI)	Mean Number of SA Updates (IRR 95% CI)
Cycle						
2 vs. 1	**2.5 (1.6,4.1)**	**2.8 (1.9, 4.0)**	**2.1 (1.4, 3.3)**	**2.4 (1.6, 3.8)**	**1.5 (1.3, 1.8)**	**2.0 (1.6, 2.5)**
3 vs. 1	**11.4 (2.65, 49.4)**	**2.6 (1.4, 5.2)**	1.3 (0.6, 2.6)	1.4 (0.6, 3.1)	**1.8 (1.4, 2.3)**	**2.1 (1.4, 3.2)**
4 vs. 1	1.8 (0.2, 17.0)	4.4 (0.5, 41.6)	-	0.0 (0.0, 0.0)	0.7 (0.2, 1.9)	1.1 (0.3, 4.0)
Population						
Mid Sized vs. Small	**1.6 (1.1, 2.3)**	1.4 (1.0, 1.9)	1.0 (0.65, 1.6)	1.0 (0.6, 1.5)	1.2 (1.0, 1.4)	1.2 (1.0, 1.6)
Large vs. Small	**1.9 (1.1, 3.4)**	**1.8 (1.1, 2.9)**	1.4 (0.8, 2.6)	1.9 (1.0, 3.6)	1.1 (0.9, 1.4)	1.2 (0.9, 1.7)
Mentorship Participation	**3.4 (1.7, 6.8)**	**3.5 (1.9, 6.3)**	1.9 (1.0, 3.5)	**2.1 (1.2, 3.9)**	**1.7 (1.3, 2.1)**	**1.8 (1.3, 2.6)**
FDA Co-Ag Funding	1.2 (0.4, 4.0)	1.6 (0.7, 3.9)	**2.7 (1.1, 6.3)**	2.1 (0.9, 4.8)	**1.5 (1.1, 2.0)**	1.6 (1.0, 2.4)
Year of Cycle						
Pre 2008	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)
Post 2008	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)